Skip to content
Study details
Enrolling now

Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

University of Colorado, Denver
NCT IDNCT06575738ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

48

Study length

about 3 years

Ages

12–24

Locations

1 site in CO

What this study is about

Researchers are testing how the body changes after bariatric surgery in adolescents. The trial will investigate why some people respond differently to this surgery and if a medication (semaglutide) can help adolescents who haven't lost enough weight after 1-2 years of bariatric surgery.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Standard postoperative care
  • 2.Receive Injectable semaglutide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

semaglutide (GLP-1 agonist; stimulates insulin release)

Drug routes

oral (Oral Tablet), injection

Endpoints

Primary: Intervention phase: Change in BMI, Observational phase: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor

Secondary: Change in 24 hour systolic blood pressure (BP), measured by ambulatory BP monitor, Intervention Phase: Number of participants with an adverse event (AE) that leads to discontinuation of the medication, measured by a count, Intervention Phase: Number of participants with at least one serious adverse event (AE) in the active medication group, measured by a count

Body systems

Endocrinology